2006
DOI: 10.1186/1471-2407-6-270
|View full text |Cite
|
Sign up to set email alerts
|

Genetic polymorphisms of MMP1, MMP3 and MMP7gene promoter and risk of colorectal adenoma

Abstract: Background: Matrix metalloproteinases (MMP) have been shown to play a role in colorectal cancer (CRC). More recently, MMP1, MMP3 and MMP7 functional gene promoter polymorphisms have been found to be associated with CRC occurrence and prognosis. To document the role of MMP polymorphisms in the early step of colorectal carcinogenesis, we investigated their association with colorectal adenoma risk in a case-control study comprising 295 patients with large adenomas (LA), 302 patients with small adenomas (SA) and 5… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
33
0
3

Year Published

2008
2008
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 58 publications
(38 citation statements)
references
References 45 publications
2
33
0
3
Order By: Relevance
“…Only Hinoda et al found a twofold in crease in CRC risk in the 6A/6A homozygotes (OR = 2.11, 95% CI: 1.163.82, P = 0.013) in the previously mentioned study of a Japanese cohort of 101 CRC patients and 127 controls. In 302 patients with small adenomas and 568 polypfree controls, the 6A/6A genotype of the 1171 MMP-3 polymorphism was associated with a significant risk of small adenomas (OR = 1.50, 95%CI: 0.992.28, P = 0.008) and this association was even stronger in individ uals with the combined genotype MMP3 1171 6A/6A + MMP1 1607 2G/2G (OR =1.88, 95%CI: 1.083.28, P = 0.001) [101] . When the MMP3 genotype of 295 patients of that study with large adenomas was compared to either the patients with small adenomas or the polypfree con trols, no difference in genotype distribution was found.…”
Section: Colorectal Cancermentioning
confidence: 93%
See 1 more Smart Citation
“…Only Hinoda et al found a twofold in crease in CRC risk in the 6A/6A homozygotes (OR = 2.11, 95% CI: 1.163.82, P = 0.013) in the previously mentioned study of a Japanese cohort of 101 CRC patients and 127 controls. In 302 patients with small adenomas and 568 polypfree controls, the 6A/6A genotype of the 1171 MMP-3 polymorphism was associated with a significant risk of small adenomas (OR = 1.50, 95%CI: 0.992.28, P = 0.008) and this association was even stronger in individ uals with the combined genotype MMP3 1171 6A/6A + MMP1 1607 2G/2G (OR =1.88, 95%CI: 1.083.28, P = 0.001) [101] . When the MMP3 genotype of 295 patients of that study with large adenomas was compared to either the patients with small adenomas or the polypfree con trols, no difference in genotype distribution was found.…”
Section: Colorectal Cancermentioning
confidence: 93%
“…Lièvre et al [101] studied the influence of genetic poly morphisms in the MMP1 (1607 1G/2G) gene in 295 pa tients with large adenomas and 302 patients with small ad enomas, the premalignant condition to colorectal cancer, and in 568 polypfree controls. No difference was found in the genotype distribution between patients with large adenomas and patients with small adenomas or healthy controls.…”
Section: Colorectal Cancermentioning
confidence: 99%
“…[12][13][14] MMP-7 thus far has not been studied in the context of BOS, although its function has been established in fibrotic lung diseases such as idiopathic pulmonary fibrosis and, in particular, the development of various cancers. [15][16][17][18][19][20][21] MMP-7 has a broad substrate specificity, being able to degrade elastin, proteoglycans, type IV collagen, and other components found in the lung matrix. 9,22 It is a protein constitutively produced by the epithelium of several noninjured, non-inflamed tissues, such as lung, liver, and breast.…”
mentioning
confidence: 99%
“…The over-expression of MMP-1 has been indicated in the poor prognosis of colorectal (28,29), esophageal (30) and bladder (31,32) cancers. MMP-1 has also been shown to be expressed by breast tumor tissue and MDA-MB-231 cells under serum-free conditions (33).…”
Section: Discussionmentioning
confidence: 99%